A closely followed crypto strategist thinks that it is almost time for altcoins to steal Bitcoin's (BTC) thunder.

Bitcoin (BTC) headed toward a “pivotal low” on Nov. 24 as manipulative traders sought to keep $100,000 out of reach. Bitcoin ...

After a huge post-election rally, Bitcoin (CRYPTO: BTC) just hit another all-time high, and is on the cusp of breaking ...

Michael Saylor is the executive chairman and co-founder of MicroStrategy, a company that issues equity and debt to buy ...

Meanwhile, the crypto market has also undergone major fluctuations, particularly with the ETH/BTC price ratio, which tracks ...

Altcoin season looms as TOTAL3 hits $936B and Layer 1 tokens rally. Pro-crypto sentiment and rising spot volumes drive market momentum.

The price of XRP (CRYPTO: XRP) has blasted over 122% higher (as of Nov. 19) since election night, vastly outperforming the ...

Discover how the YieldMax MSTR Option Income Strategy ETF (MSTY) maximizes gains through call-option-selling strategy in high ...

Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer ...

Analyzing the risks and benefits of investing in MSTY and MSTR in a volatile market influenced by BTC/USD movements.

If the Senate confirms Bessent, the next person whose signature is on the front of paper U.S. currency will be a fan of ...

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with ...